Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=-awardee_organization
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-awardee_organization", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1397&sort=-awardee_organization", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-awardee_organization", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-awardee_organization" }, "data": [ { "type": "Grant", "id": "15292", "attributes": { "award_id": "1F31HD115324-01", "title": "Associations among maternal stress, infant epigenetics, and behavioral and cognitive development across the first few years of life", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 8605, "first_name": "JAMES", "last_name": "GRIFFIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2026-07-31", "award_amount": 42574, "principal_investigator": { "id": 31883, "first_name": "Jessica", "last_name": "Sperber", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2526, "ror": "", "name": "COLUMBIA UNIVERSITY TEACHERS COLLEGE", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "This F31 NRSA application will provide the applicant with the training necessary to achieve their goal of becoming an independently-funded researcher integrating perspectives from developmental psychology, neuroscience, and prevention science. This dissertation project seeks to incorporate epigenetic aging as a biomarker and potential mechanism to explain the association between maternal stress and behavioral and cognitive development over the first few years of life. The application proposes training in: 1) the integration of epigenetic aging into the larger study of maternal stress and child development; 2) the methodology for DNA methylation extraction and analysis; and 3) advanced longitudinal models. The sponsorship team consists of experts in the fields of Psychology, Neuroscience, and Education from both Teachers College, Columbia University and University of Texas-Austin. The resources afforded by these sponsors and institutions will facilitate the applicant’s goal of integrating multimodal and interdisciplinary methods to improve the trajectories of children experiencing early life stress. RESEARCH PROJECT: Maternal stress during pregnancy and early childhood is a robust predictor of deleterious outcomes for children’s cognitive and behavioral development. Epigenetic processes are a powerful mechanism to explain how adverse experiences biologically embed to predict later functioning. Accelerated aging reflects a biological age that exceeds one’s chronological age, and is tightly linked with both early life stress and negative physical and mental health outcomes in adults. However, little is understood about these associations during early childhood. The reported spike in maternal stress since the onset of the COVID- 19 pandemic highlights the urgency with which researchers must examine how stress biologically embeds to predict later functioning. The present study will leverage an existing birth cohort of socioeconomically diverse families from New York City to examine the longitudinal associations among maternal stress, accelerated aging, and cognition and behavioral regulation in early childhood, with the following Aims: 1) Examine the longitudinal, stress-related alterations in epigenetic age across early childhood; 2) Examine biomarkers and cognitive effects of the COVID-19 pandemic in mothers and children; and 3) Examine whether accelerated aging predicts cognition and behavioral regulation in childhood. Maternal stress will be assessed both prenatally and at various points throughout the first three of years of the child’s life. Both perceived and physiological measures of stress will be examined in these associations. Children will provide saliva samples at 1-month and 30-months of age to examine epigenetic age and complete well-validated assessments of cognition and behavioral regulation at 30- months. Findings will elucidate the relationships between maternal stress and accelerated aging during childhood and the functional relevance of accelerated aging to children’s behavior and cognition.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15287", "attributes": { "award_id": "1R43DA060696-01", "title": "Software as a Medical Device for detecting opioid use through voice.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Drug Abuse (NIDA)" ], "program_reference_codes": [], "program_officials": [ { "id": 12311, "first_name": "LEONARDO MARIA", "last_name": "Angelone", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-01", "end_date": "2025-07-31", "award_amount": 400000, "principal_investigator": { "id": 31875, "first_name": "Rima", "last_name": "Seiilova-Olson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2525, "ror": "", "name": "TENVOS INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Patients affected by opioid use disorder (OUD) face numerous challenges, ranging from stigma to policy barriers that impede their access to care. Even after engaging OUD patients in treatment, retention rates are disappointingly low due to a multitude of factors. Despite the widespread adoption of virtual counseling and treatment solutions, such as telemedicine programs using medications for opioid use disorder (MOUD), during the COVID-19 pandemic, addiction treatment still requires in-person visits for regular drug testing. However, this requirement can lead to non-compliance and being dropped from what is often their only therapeutic option available. Innovative and FDA-cleared opioid use testing methods that can be performed outside of laboratory environments address these issues and hold the promise of increasing retention rates and improving clinical outcomes. Tenvos’ product will be integrated into a smartphone app, enabling patients to test for opioid use from the comfort of their home and send instant results to the clinician without the need for an in-person visit. The proposed solution will not only improve clinical outcomes in the outpatient OUD treatment setting but can be adopted in many other settings due to its convenience and can, potentially, unlock new workflows that were not feasible before. The FDA-regulated SaMD itself, which is a ML-based solution, will be exposed through an API enabling its integration into a large number of systems and applications. The API can be integrated into virtual health solutions and provide opioid use assessment real-time during an appointment. It can be integrated into a wearable device and serve as a remote patient monitoring device that notifies the treating physician in case of a relapse. It can also be used for population health and risk stratification by integrating into case management calls at managed care organizations to identify individuals who may benefit from OUD treatment. The specific aims for the Phase I set of activities include: Aim 1: Collecting clinical data with gold standard test results and patient voice samples to study the correlation between them. Aim 2: Validating and fine-tuning the machine learning models with the collected clinical data. Aim 3: Engaging with the FDA Center of Devices and Radiological Health (CDRH) through a pre-submission process to obtain feedback on the most appropriate pathway, such as PMA, De Novo, or 510(k).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15280", "attributes": { "award_id": "1R16AI184450-01", "title": "Determining the role of AnnexinA2 in HIV-1 and SARS-CoV-2 assembly", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 27781, "first_name": "Mary Katherine Bradford", "last_name": "Plimack", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-12", "end_date": "2028-07-31", "award_amount": 180599, "principal_investigator": { "id": 31868, "first_name": "PETER William", "last_name": "RAMIREZ", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2524, "ror": "", "name": "CALIFORNIA STATE UNIVERSITY LONG BEACH", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Human Immunodeficiency Virus Type 1 (HIV-1) and Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) are two enveloped RNA viruses that affect significant proportions of the global population. HIV- 1 and SARS-CoV-2 rely on lipid rafts to facilitate viral entry, assembly, and release, but the exact mechanisms for how this occurs remain unclear. Lipid rafts represent distinct regions within cellular membranes that are enriched in cholesterol, glycophospholipids, and protein receptors. Disrupting lipid-raft formation pharmacologically reduces both HIV-1 and SARS-CoV-2 infection. Our long-term goal is to determine how viruses hijack cellular proteins to disarm host defenses and co-opt cellular pathways to promote infection. The objective in this application is to determine how the lipid-raft scaffold protein AnnexinA2 facilitates HIV-1 and SARS-CoV-2 assembly. Our preliminary data suggest that AnnexinA2 interacts with two distinct viral membrane proteins: HIV-1 Nef and SARS-CoV-2 Spike. Our central hypothesis is that AnnexinA2 facilitates the localization of Nef and Spike to lipid-raft compartments, thereby augmenting viral assembly and infectivity. The rationale for this project is that identifying specific mechanisms by which HIV-1 and SARS-CoV-2 exploit AnnexinA2 to enhance viral infection will open new aspects of viral biology and offer new therapeutic strategies. We aim to test our hypothesis by pursuing two specific aims: 1) Identify how AnnexinA2 facilitates HIV-1 infection; and 2) Determine how AnnexinA2 promotes SARS-CoV-2 replication. In Aim 1, we will validate whether Nef directly binds to AnnexinA2, determine whether the Nef/AnnexinA2 interaction correlates with the enhanced prevalence of HIV-1, map the molecular determinants required for interaction, and determine whether AnnexinA2 enriches Nef in lipid-rafts at the cell surface. Additionally, we will knockout AnnexinA2 via CRISPR/Cas9 in primary cells to determine whether Nef requires AnnexinA2 to enhance infectivity. For Aim 2, we will produce SARS-CoV-2 Virus Like Particles (SC2-VLPs) in both the presence and absence of AnnexinA2 to determine its role in facilitating SARS-CoV-2 assembly. We will also validate the SARS-CoV-2 Spike/AnnexinA2 interaction and delineate whether AnnexinA2 recruits Spike to lipid rafts at the ER-Golgi Intermediate Compartment (ERGIC). The proposed research is innovative and significant because it will generate novel models of retrovirus and coronavirus biology, vertically advancing both fields and providing novel avenues for further mechanistic and therapeutic investigation.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15260", "attributes": { "award_id": "1OT2DA061146-01", "title": "PERSON-CENTERED RESEARCH ON CULTURE AS HEALTH (PERCH) An Indigenous Model of Wellness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23270, "first_name": "BARBARA ANN", "last_name": "Oudekerk", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-23", "end_date": "2025-07-31", "award_amount": 593970, "principal_investigator": { "id": 31848, "first_name": "Christina", "last_name": "Denslinger", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31849, "first_name": "Kade", "last_name": "Lenz", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2523, "ror": "", "name": "GREAT LAKES INTER-TRIBAL COUNCIL, INC.", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "NIH HEAL Initiative N CREW Great Lakes Inter-Tribal Council PERSON-CENTERED RESEARCH on CULTURE AS HEALTH (PERCH) An Indigenous Model of Wellness Abstract. Native American (NA) youth in the Bemidji area grapple with the opioid epidemic's harshest consequences, experiencing a devastating 68% rise in opioid-related deaths since 2019 (GLITEC, 2021). The COVID-19 pandemic further compounded this crisis, with opioid-related deaths spiking by 33.5% between 2019 and 2020. These alarming rates of substance use among NA youth stem from underlying mental health issues fueled by historical trauma, unresolved needs due to long-standing social inequalities, and the broader social determinants of health. In response to this urgent crisis, the Great Lakes Inter-Tribal Council (GLITC) has conducted extensive research and is pioneering the Adolescent Recovery Wellness Center (ARWC), a first-of-its-kind residential facility for youth aged 13-17 struggling with substance use disorder (SUD) and co-occurring mental health conditions. From the beginning, GLITC's focus has been on the development of a Person-Centered approach and integration of Tribal wellness practices. The N CREW HEAL initiative fuels this development of a research program named Person-centered Research on Culture as Health (PERCH). The three AIMS are to build capacity to engage in research: 1) Establish and register the GLITC Institutional Review Board (IRB); 2) Plan for long-term success and sustainability through development and demonstration of culturally appropriate and effective recovery and treatment services for NA youth; and 3) Establish a culturally specific Healthcare Model to sustainably support NA Youth with SUD and other co-occurring Mental Behavior Health conditions. GLITC’s plan is to operate the ARWC to address the unique health challenges faced by native youth, and stands as a symbol of resilience, strength, and the profound impact of integrating traditional and modern pathways to healing and wellness. Through this innovative approach & methodology, the ARWC’s operational plan will include a Cultural Competency Framework for treatment and an Indigenous Evaluation Framework that uses mixed methods statistical approaches to build a Convergence of Evidence Model demonstrating traditional wellness practices are effective and therefore should qualify as billable healthcare services. The Outcomes are integration of traditional health practices to strengthen cultural connectivity, improve mental behavioral wellness, and reduce risky behaviors in NA youth. Related wrap around services in tribal communities will integrate a compassionate Person-Centered healthcare model culturally defined and evidence-based to reduce SUD in NA youth.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15226", "attributes": { "award_id": "1U01AI184132-01", "title": "Clinical and mechanistic studies defining optimal preparative approaches to infants with IL2RG/JAK3/RAG1/RAG2 SCID: a randomized trial of busulfan dosage", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31806, "first_name": "Margaret A.", "last_name": "Morris Fears", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-13", "end_date": "2029-05-31", "award_amount": 1072951, "principal_investigator": { "id": 31807, "first_name": "JEFFERY J", "last_name": "AULETTA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 31808, "first_name": "Michael A", "last_name": "Pulsipher", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2522, "ror": "https://ror.org/016cke005", "name": "National Marrow Donor Program", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe combined immunodeficiency (SCID) is a group of genetic disorders that abrogate T cell development and function. Allogeneic hematopoietic cell transplantation (HCT) is the standard treatment for the disease and can be performed successfully in SCID patients without the high dose pre-HCT busulfan conditioning due to the unique capacity for progenitors to engraft in the empty thymus and reconstitute T cell development. Without conditioning, lineages other than T cells remain of host origin. The CSIDE protocol was funded with an earlier grant to test the efficacy and safety of a regimen of low dose, individualized targeted busulfan compared to moderate dose in SCID patients at risk of poor humoral outcome undergoing non-matched sibling donor HCT. We hypothesize that patients randomized to receive low dose busulfan will achieve similar outcomes compared to those receiving moderate dose (myeloablative) busulfan, achieving both T and B cell immune reconstitution. Due to COVID and competition with gene therapy, accrual slowed, but with 50 centers open and a redesigned approach, additional enrollment facilitated by this grant will ensure that the trial reaches meaningful conclusions. In Aim 1, patients have been randomized to cumulative area-under-the-curve (cAUC) exposure of busulfan of 30 mg*h/L versus 60 mg*h/L. IL2RG/JAK3 patients also receive rATG, while RAG1/2 patients receive rATG, fludarabine, and thiotepa. Stem cell sources include unrelated and haploidentical related donor products that have been TCRαβ+/CD19+ depleted with no post-HCT GVHD prophylaxis. The safety profile of the trial has been excellent to date. The original primary endpoint was protective antibody response to tetanus by 2 years post-HCT. Because of enrollment challenges, we redesigned the primary endpoint into an ordinal ranked win comparison, which allows higher power even if we cannot fully enroll. The primary outcome will center around the IL2RG/JAK3 cohort, which should achieve full accrual, randomizing 32 patients. The RAG1/2 cohort will close once the IL2RG/JAK3 cohort closes, likely accruing up 18-20 patients which we will analyze descriptively. In Aim 2, We hypothesize that donor HSC engraftment measured by the surrogate of myeloid donor chimerism will be associated with superior quality of T cell reconstitution and improved adaptive immune responses to vaccination. We hypothesize that T cell exhaustion and poor T cell receptor (TRB) diversity seen in patients undergoing HCT in the absence of conditioning will be diminished or absent in CSIDE participants due to improvements in thymic output associated with engraftment of donor-derived HSC. We hypothesize that IL2RG/JAK3 patients receiving moderate dose busulfan and/or with high level donor chimerism will exhibit multiple in vitro biomarkers of IL-21 response, as this cytokine signals via IL2RG/JAK3. We hypothesize that vaccine response will correlate with normalization of IGH CDR3 diversity in RAG1/2 patients with mixed chimerism due to strong selective advantage for antigen-specific B cells. We hypothesize that T cell tolerance will occur by different mechanisms (central deletion versus peripheral regulation) according to donor type. Finally, we hypothesize that analysis of pK samples for elements of our preparative approaches (rATG, thiotepa, and fludarabine) will allow targeted treatment of infants undergoing HCT for SCID or other disorders moving forward.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15220", "attributes": { "award_id": "1R43GM155491-01", "title": "Developing Technology to Remotely Measure Molecular Composition", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 23882, "first_name": "CHARLES ASHLEY", "last_name": "Barnes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2025-08-31", "award_amount": 258586, "principal_investigator": { "id": 31801, "first_name": "Sarah", "last_name": "Trimpin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2521, "ror": "", "name": "MSTM, LLC", "address": "", "city": "", "state": "DE", "zip": "", "country": "United States", "approved": true }, "abstract": "There is a critical need for accurate and safe early stage detection of, e.g., infectious diseases, hazardous materials, and other health related issues. Remote detection directly from surfaces, especially related to health concerns (in situ, in vivo) is an underserved area of immense utility. Thus, significant commercial opportunities exist because of the dearth of these capabilities as “demonstrated” in the current double pandemics of Covid and drugs as well as persistent threats (bacterial, fungi, cancers, bioagents, etc.). Mass spectrometry (MS), because of its ability to detect hundreds of biological compounds in a single acquisition provides the capability to distinguish chemical differences associated with, e.g., different pathogens and disease states, as well as target specific compounds in or on surfaces or within compositions (e.g., drugs from Skittles), as examples. Current MS approaches use ionization methods requiring user expertise and frequently specialized instrumentation, which significantly increases cost. Over the past 30 years, mass spectrometers have undergone a renaissance in their cost-to-capability ratio. For more widespread applications of MS in advancing healthcare, there is a need for new advanced direct sampling / ion source technology that provides for minimal user intervention and long-term use without maintenance. These attributes are necessary if testing of hundreds of individual surfaces daily per instrument to e.g., identify, track, and contain the spread of infectious agents, or to detect cancer in biopsied tissue or cancer boundaries during surgery is to be implemented using MS in the future. The goal of this NIH SBIR Phase I project is to demonstrate that an entirely new sampling device-transfer-ionization approach constitutes a disruptive technology and effective method that can be used for the next-generation disease detection and health management. The basic invention of this project is covered by two MSTM provisional patent applications (April 3 and June 5, 2023), and earlier IP from inventors Trimpin (CEO of MSTM) and McEwen (President of MSTM) exclusively licensed from two universities to MSTM. In summary, these developments and remote sampling research position MSTM well for advancing this exciting area in need of new technology. Critical advantages include exceptional ease and flexibility, on the fly results, remote sampling of 3- dimensional surfaces without and with the use of a laser, robustness to instrument contamination and carryover, and the capability to retrofit with commercial atmospheric pressure ionization mass spectrometers to provide accurate, safe, detection on demand. The objective of this Phase I project is to demonstrate the feasibility and proof-of-concept of the surface reader to sample surfaces directly with a liquid meniscus or indirectly by laser ablation. In Phase II, an FDA approved CO2 laser will be implemented along with machine learning algorithms in a commercial product requiring little expertise to effectively operate. Aim 1: Build a proof-of-concept remote surface reader interfaced with an MSTM multiport inlet using SAI and VSAI MS for differentiation of diseased vs. normal tissue through computer aided m/z fingerprint recognition. Aim 2: Test the remote transfer device of Aim 1 using real samples for demonstration and Phase II purposes. MSTM has the necessary expertise and facilities to bring this Phase I project to a successful conclusion within 12 months. MSTM has enlisted help from knowledgeable companies (letters Advion, Bruker, Medtronic, Thermo, BioPharmaSpec).", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15203", "attributes": { "award_id": "1R01AG089307-01A1", "title": "Heat Therapy for the treatment of post-acute COVID-19 syndrome", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8342, "first_name": "Marcel", "last_name": "Salive", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-03", "end_date": "2029-08-31", "award_amount": 657088, "principal_investigator": { "id": 31786, "first_name": "GWENAEL", "last_name": "LAYEC", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2520, "ror": "", "name": "UNIVERSITY OF NEBRASKA OMAHA", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "Post-acute sequelae of SARS-CoV-2 infection (PASC) affects 5 out of 10 patients hospitalized for the coronavirus disease 2019 (COVID-19) and ~11% of all adults infected by SARS-CoV-2, which makes this condition a growing public health concern. It is associated with important disabilities, cognitive dysfunction, and increased risks for cardiovascular and metabolic diseases. Although exercise-based intervention is a promising rehabilitation strategy, participation rates are commonly low in clinical population. In addition, post-exertional malaise, a common symptom with PASC, is a major safety concern in these patients, which may prevent a significant proportion of these individuals to receive adequate rehabilitation. In this context, there is a critical need to develop well-tolerated and effective strategies at home that ameliorates health and functional capacity in individuals with PASC. One promising approach that offers numerous health benefits is whole-body heat therapy. Whether this intervention is effective when confined to the lower body and well tolerated at home in people with PASC is, however, unknown. The overall objective of this project is to determine the safety, tolerability, and efficacy of home-based lower body heat therapy in late middle-age and older adults with PASC. We will test the central hypothesis that home-based lower body heat therapy is safe, well adhered, and can improve functional capacity and several surrogate markers for metabolic and vascular health in late-middle age and older adults with PASC. Specific Aim 1 will test the hypothesis that lower body heat therapy at home is safe, well adhered, and improve both cognitive and physical function in middle-age and older adults with PASC. Selected participants will be randomly allocated to perform 8 weeks of home-based lower body heat therapy (HT, skin temperature 38-40˚C, 40-55 min, 5 per week at home), a thermoneutral condition (CT, skin temperature 33˚C, same duration and frequency), or a walking intervention using wearable technology (WT, 1,500-3,000 additional steps from baseline, 3-5 days per week). We will compare the 6 min walking distance, the short physical performance battery test score, gait speed, cognitive function, incidence of adverse events, and participant’s adherence to intervention between groups. Specific Aim 2 will test the hypothesis that heat therapy will attenuate inflammation, which will then decrease arterial stiffness, and improve both vascular endothelial function and muscle intracellular O2 availability in individuals with PASC. We will use in vitro assays on blood samples and Doppler ultrasound techniques to assess changes in inflammation, redox status, pulse- wave velocity, and flow-mediated dilation. Muscle intracellular O2 availability will be measured by magnetic resonance spectroscopy in vivo. Specific Aim 3 will test the hypothesis that lower body heat therapy will improve glucose control as a result of enhanced mitochondrial function. All these effects will not be statistically inferior to the WT group. The proposed research is highly significant as it is easily translatable and is expected to guide future rehabilitation strategies to mitigate long-term disabilities in patients with PASC.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15345", "attributes": { "award_id": "1R44HL174366-01A1", "title": "Personal Respiratory Isolation System for Safe Transport and Treatment of Patients with Highly Transmissible Infectious Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 22653, "first_name": "EMMANUEL FRANCK", "last_name": "Mongodin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-18", "end_date": "2026-03-31", "award_amount": 842408, "principal_investigator": { "id": 31784, "first_name": "Sridhar", "last_name": "Kota", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2519, "ror": "", "name": "INSPIRE RX LLC", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: The goal of this project is to develop a solution that allows for rapid, safe, and scalable initial treatment and transport of patients with highly transmissible infectious diseases, including COVID-19 as well influenza, tuberculosis, chickenpox, and measles. This is a necessary innovation because resource management and infectious transmission control were two of the greatest challenges healthcare providers faced when fighting the COVID-19 pandemic. When a patient is suffering from highly transmissible respiratory diseases and requires breathing assistance, they are placed in negative pressure rooms. However, given the limited supply of negative pressure rooms available to prevent virus transmission, and the misperception regarding the safety and effectiveness of negative pressure rooms, a new solution is needed. To help prevent the spread of highly transmissible infectious diseases, start-up company Inspire Rx has developed a personal negative pressure device called the AerosolVE™ BioHelmet. The BioHelmet is capable of preventing the spread of aerosolized pathogens while also enabling the use of non-invasive oxygen therapies on patients with respiratory diseases such as COVID-19, influenza, tuberculosis, etc. The negative pressure AerosolVE™ BioHelmet immediately isolates patients with any highly transmissible respiratory infectious disease and serves as an instant personal negative pressure environment that is more effective than a traditional negative pressure room. The BioHelmet is intended to provide safe transportation via ambulance, airplane, or helicopter, allowing critical transportation staff to remain safe, and it will be valuable in a variety of other healthcare settings. In this project the team will refine and further evaluate the AerosolVE BioHelmet, and they will leverage data from their previous in-cabin particle testing to advance the BioHelmet as an effective tool at keeping a vehicle/transport cabin free from potentially pathogenic respiratory particles. They will first refine the BioHelmet design to reduce noise and weight, and they will fabricate 100 AerosolVE BioHelmets and 20 pump units for follow-on bench testing and clinical user evaluations (Aim 1). They will conduct performance and bench testing at FDA-approved labs to ensure the safety and efficacy of the AerosolVE BioHelmet per FDA guidelines (Aim 2). They will deploy the helmet for clinical patient use during ground and air ambulance transportation of patients with suspected or confirmed communicable respiratory illness, including those requiring potential aerosol-generating procedures, and the purpose of this will be to obtain user feedback on comfort and east of use from patients and providers (Aim 3). The BioHelmet will provide a novel, compact, portable, and inexpensive solution that offers a safe negative pressure environment both inside and outside the hospital, which will ultimately save lives by allowing for needed patient treatments and protecting healthcare workers.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15201", "attributes": { "award_id": "1R43OH012719-01", "title": "Protecting Healthcare Workers Using a Patient-Worn Negative Pressure System to Prevent the Spread of Highly Transmissible Infectious Diseases", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute for Occupational Safety and Health (NIOSH)" ], "program_reference_codes": [], "program_officials": [ { "id": 31783, "first_name": "Marcienne Michele", "last_name": "Wright", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2025-08-31", "award_amount": 295924, "principal_investigator": { "id": 31784, "first_name": "Sridhar", "last_name": "Kota", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2519, "ror": "", "name": "INSPIRE RX LLC", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "The goal of this project is to develop a solution that allows for rapid, safe, and scalable initial treatment and transport of patients with highly transmissible infectious diseases. This is a necessary innovation because resource management and infectious transmission control were two of the greatest challenges healthcare providers faced when fighting the COVID-19 pandemic. When a patient is suffering from highly transmissible respiratory diseases and requires breathing assistance, they are placed in negative pressure rooms. However, given the limited supply of negative pressure rooms available to prevent virus transmission, and the misperception regarding the safety and effectiveness of negative pressure rooms, a new solution is needed. To help prevent the spread of highly transmissible infectious diseases, start-up company Inspire Rx has developed a personal negative pressure device called the AerosolVE™ BioHelmet. The BioHelmet is capable of preventing the spread of aerosolized pathogens while also enabling the use of non-invasive oxygen therapies on patients with respiratory diseases such as COVID-19, influenza, tuberculosis, measles, and chicken pox. The negative pressure AerosolVE™ BioHelmet immediately isolates patients with any highly transmissible respiratory infectious disease and serves as an instant personal negative pressure environment that is more effective than a traditional negative pressure room. The BioHelmet is intended to provide safe transportation via ambulance, airplane, or helicopter, allowing critical EMS and transportation staff to remain safe, and it can also be used in any area of a hospital (including waiting rooms, hallways, imaging facilities, and any patient room). In this project the team will refine and further evaluate the AerosolVE BioHelmet, building on their preliminary data collected during the COVID-19 pandemic. They will first refine the BioHelmet design and fabricate 5 AerosolVE BioHelmets and pump units for follow-on bench testing and obtaining end-user feedback (Aim 1). They will conduct performance and bench testing for the different device components of the BioHelmet to demonstrate that the device performs as expected for its intended use, including particulate testing (Aim 2). Finally, they will obtain end-user feedback from clinicians, hospital administrators, and others to inform final design requirements (Aim 3). In a future Phase II grant, they will conduct performance and bench testing in FDA approved labs to ensure safety and efficacy, as well as clinical testing to ensure the BioHelmet can be comfortably worn for an extended period (several days). They will then submit an FDA 510(k) application to enable commercialization. The BioHelmet will provide a novel, compact, portable, and inexpensive solution that offers a safe negative pressure environment both inside and outside the hospital, which will ultimately save lives by protecting healthcare workers while treating patients.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15194", "attributes": { "award_id": "1R43OH012683-01", "title": "Voice Amplifier to Enhance Occupational Safety and Critical Care among Masked Providers", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute for Occupational Safety and Health (NIOSH)" ], "program_reference_codes": [], "program_officials": [ { "id": 24462, "first_name": "BRIDGETTE E", "last_name": "GARRETT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-01", "end_date": "2025-08-31", "award_amount": 357231, "principal_investigator": { "id": 31774, "first_name": "Matthew", "last_name": "Hilden", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2518, "ror": "", "name": "MINNESOTA HEALTHSOLUTIONS CORPORATION", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The proposed project relates to the development of a technological intervention to improve speech intelligibility among healthcare workers who wear personal protective equipment for occupational safety while caring for patients with infectious diseases. Respiratory protective equipment such as filtering facepiece respirators, elastomeric half- and full-facepiece respirators and powered air-purifying respirators are routinely worn in the critical care unit as components of personal protective equipment for occupational safety when caring for patients with infectious diseases including COVID-19. Diminished speech intelligibility has been observed to be associated with certain types of respiratory protective equipment. Effective verbal exchanges are vital in critical care and significant reductions in speech intelligibility impact many complex tasks. The objective of this proposed scientifically rigorous phase I project is to specify, design, construct, test and evaluate a fully functional prototype system to improve speech intelligibility among healthcare workers wearing respiratory protective equipment. The system will be designed for use in a healthcare environment and be compatible with a wide variety of respiratory protective equipment.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1397, "count": 13961 } } }